Back to homepage

Immunology

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Authors: Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.

More▸

Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

This review focuses on the mechanisms of action, routes of administration, and efficacy of therapies for the rare genetic disorder hereditary angioedema.

More▸

Targeting eosinophils: severe asthma and beyond

Authors: Marco Caminati MD, Francesco Menzella MD, Lucia Guidolin MD, Gianenrico Senna MD

This review summarizes the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action.

More▸

Guselkumab for the treatment of psoriasis – evidence to date

Authors: Miguel Nogueira MD, Tiago Torres MD, PhD

This review highlights the evidence available to date for the use of guselkumab for the treatment of psoriasis. The results of the recent ECLIPSE trial are addressed.

More▸

Novel therapeutic targets for allergic airway disease in children

Authors: Alessandro Giallongo MD, Giuseppe Fabio Parisi MD, Amelia Licari MD, Giulio Pulvirenti MD, Caterina Cuppari MD, Carmelo Salpietro MD, Gian Luigi Marseglia MD, Salvatore Leonardi MD

Keywords: allergic airway disease, allergic rhinitis, asthma, biologics, children, chronic rhinosinusitis, immunotherapy. Citation: Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Novel therapeutic targets for allergic airway disease in children. Drugs in

More▸